NDA 201849 · Fresenius Kabi USA
Glucagon
Glucagon Hydrochloride · Intramuscular, Intravenous, Subcutaneous, Intramuscular, Intravenous
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
May 8, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,154
249 Phase 3, 171 recruiting
FAERS reports
3,600
2,995 serious, 635 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 31, 2025.
Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ( 1.1 ) as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients ( 1.2 ) 1.1 Severe Hypoglycemia Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. 1.2 Diagnostic Aid Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
Mechanism: Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 9, 2019 Supplement 5 · Efficacy LetterLabel
- May 8, 2015 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetter
2 products under this application
- GLUCAGON · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL · POWDER, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Prescription
- GLUCAGON · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL · POWDER, INTRAMUSCULAR, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Glucagon" as an intervention, any sponsor and status, largest first.
- High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention ProgramPivotal-lookingStatus unknown
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT05782881 · 16,000 participants (planned) · Start Jan 15, 2023 · Primary completion Dec 31, 2023
Drug: Statin · For: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Coronary Disease
Sites: Enshi, China; Ezhou, China; Huanggang, China · 107 sites in all
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05556512 · 15,374 participants · Start Oct 11, 2022 · Primary completion Oct 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 672 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04255433 · 13,299 participants · Start May 29, 2020 · Primary completion Jun 12, 2025
Drug: Tirzepatide; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Concord, California; Covina, California · 635 sites in all
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02465515 · 9,463 participants · Start Jul 1, 2015 · Primary completion Feb 20, 2018
Drug: Albiglutide 30 mg; Albiglutide 50 mg and 1 more · For: Diabetes Mellitus
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 607 sites in all
- Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01179048 · 9,341 participants · Start Aug 31, 2010 · Primary completion Dec 17, 2015
Drug: liraglutide; placebo · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Alabaster, Alabama; Birmingham, Alabama; Huntsville, Alabama · 428 sites in all
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea362
- drug ineffective332
- acute kidney injury323
- hypotension298
- condition aggravated257
- toxicity to various agents237
- haemoptysis224
- anxiety221
- hypoglycaemia207
- pain in extremity207
- asthma196
- off label use193
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 24 |
| 2006 | 20 |
| 2007 | 26 |
| 2008 | 23 |
| 2009 | 49 |
| 2010 | 34 |
| 2011 | 53 |
| 2012 | 53 |
| 2013 | 54 |
| 2014 | 83 |
| 2015 | 230 |
| 2016 | 202 |
| 2017 | 210 |
| 2018 | 207 |
| 2019 | 305 |
| 2020 | 353 |
| 2021 | 316 |
| 2022 | 226 |
| 2023 | 303 |
| 2024 | 297 |
| 2025 | 306 |
| 2026 | 207 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.
Berg S, Stickle H, Rose SJ, et al. · Obes Rev 2025 · Meta-Analysis, Systematic Review
- The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.
Radkhah H, Rahimipour Anaraki S, Parhizkar Roudsari P, et al. · Eat Weight Disord 2025 · Systematic Review, Meta-Analysis
- Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis.
Elkin J, Rele S, Sumithran P, et al. · Anaesthesia 2025 · Meta-Analysis, Systematic Review
- Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
Saglietto A, Falasconi G, Penela D, et al. · Eur J Clin Invest 2024 · Meta-Analysis, Systematic Review
- Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
Silverii GA, Monami M, Gallo M, et al. · Diabetes Obes Metab 2024 · Meta-Analysis, Systematic Review
- Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.
Iqbal J, Wu HX, Hu N, et al. · Obes Rev 2022 · Meta-Analysis, Systematic Review
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.